Oncogenic osteomalacia: Loss of hypophosphatemia might be the key to avoid misdiagnosis

Claudia V. Chang, Sandro J. Conde, Renata A.M. Luvizotto, Vânia S. Nunes, Milla C. Bonates, Andre C. Felicio, Susan C. Lindsey, Flávia H. Moraes, José V. Tagliarini, Glaucia M.F.S. Mazeto, Peter Kopp, Célia R. Nogueira

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


Diagnosing oncogenic osteomalacia is still a challenge. The disorder is characterized by osteomalacia caused by renal phosphate wasting and low serum concentration of 1,25-dihydroxyvitamin D3 occurring in the presence of a tumor that produces high levels of fibroblast growth factor 23. However, it is possible that the disease is much more misdiagnosed than rare. We present the case of a 42-year-old man with a long-term history of undiagnosed progressive muscle weakness. His laboratory results mainly showed low serum phosphate. Surgical removal of a nasal hemangiopericytoma that had been diagnosed five years earlier, brought him to a symptom-free condition. Even though knowing the underlying etiology would explain his osteomalacia, the patient sought medical help from countless physicians for five consecutive years, and only after adequate treatment a rewarding outcome was achieved.

Original languageEnglish (US)
Pages (from-to)570-573
Number of pages4
JournalArquivos brasileiros de endocrinologia e metabologia
Issue number8
StatePublished - Nov 2012

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism


Dive into the research topics of 'Oncogenic osteomalacia: Loss of hypophosphatemia might be the key to avoid misdiagnosis'. Together they form a unique fingerprint.

Cite this